RSS Feed ALL

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

1 day ago

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9...

Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

4 days ago

Phase 1b study suggests a promising safety profile and highlights the potential...

New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

5 days ago

Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for...

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison

5 days ago

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax...

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

6 days ago

TREMFYA ® demonstrated two and a half times greater ability to inhibit...

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

6 days ago

Johnson & Johnson Launches the ETHICON™ 4000 Stapler for Elevated Surgical Experience and the Most Secure Staple Line Yet1

7 days ago

The stapling system features ETHICON™ 3D Reloads with proprietary 3D Stapling Technology...

Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients

14 days ago

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

14 days ago

More than half of patients maintained minimal residual disease (MRD) negativity (10-5)...

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

14 days ago

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI® remain...

Johnson & Johnson Launches KINCISE™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures

14 days ago

Next-generation system delivers control1,2,3 while expanding surgical applications4* across primary and revision...

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

14 days ago

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA®...